ALK and non-small cell lung carcinoma: The phase I/II study of AP26113 included 137 pts with advanced malignancies, including 79 pts with ALK-rearranged NSCLC, of whom 52 (66 %) of 79 ALK+ NSCLC pts had BM at baseline [21].